Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

ClinicalTrials.gov ID: NCT01654263

Public ClinicalTrials.gov record NCT01654263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Study identification

NCT ID
NCT01654263
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
884 participants

Conditions and interventions

Interventions

  • Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] Biological

Biological

Eligibility (public fields only)

Age range
55 Years to 74 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2012
Primary completion
Aug 20, 2015
Completion
Aug 20, 2015
Last update posted
Mar 26, 2017

2012 – 2015

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Emory Vaccine Center - The Hope Clinic Decatur Georgia 30030-1705
University of Iowa - Vaccine Research and Education Unit Iowa City Iowa 52242-2600
Saint Louis University - Center for Vaccine Development St Louis Missouri 63104-1015
Cincinnati Children's Hospital Medical Center - Infectious Diseases Cincinnati Ohio 45229-3039
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center Nashville Tennessee 37232-2573
Baylor College of Medicine - Molecular Virology and Microbiology Houston Texas 77030-3411
Group Health Research Institute - Seattle - Vaccines and Infectious Diseases Seattle Washington 98101-1466

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01654263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 26, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01654263 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →